Anemia is a common complication in chronic kidney disease (CKD), and is associated with a
reduced quality of life, and an increased morbidity and mortality. The mechanisms involved …

The hepatic iron-regulatory hormone hepcidin and its receptor, the cellular iron exporter
ferroportin, constitute a feedback-regulated mechanism that maintains adequate plasma …

In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and
associated with significant adverse consequences. In 2012, Kidney Disease: Improving …

Background Current anemia therapies for patients with non–dialysis-dependent CKD may
require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl …

Abstract Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl
hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb …

Background The optimal iron therapy regimen in patients with non-dialysis-dependent
chronic kidney disease (CKD) is unknown. Methods Ferinject® assessment in patients with …

Chronic kidney disease (CKD), defined by an estimated glomerular filtration rate< 60
ml/min/1.73 m2 and/or an increase in urine protein excretion (ie, albuminuria), is an …

Background Anemia is associated with adverse outcomes in those with chronic kidney
disease (CKD). We examined the association of absolute and functional iron deficiency …

Background No study has assessed whether the prognosis of coexisting diabetes mellitus
and chronic kidney disease (DM-CKD) is dictated by DM per se or by the extent of …

Objective: To evaluate the efficacy of IV iron supplementation of anemic, critically ill trauma
patients. Design: Multicenter, randomized, single-blind, placebo-controlled trial. Setting …